AU2001282832A1 - New use of quetiapine - Google Patents

New use of quetiapine

Info

Publication number
AU2001282832A1
AU2001282832A1 AU2001282832A AU8283201A AU2001282832A1 AU 2001282832 A1 AU2001282832 A1 AU 2001282832A1 AU 2001282832 A AU2001282832 A AU 2001282832A AU 8283201 A AU8283201 A AU 8283201A AU 2001282832 A1 AU2001282832 A1 AU 2001282832A1
Authority
AU
Australia
Prior art keywords
quetiapine
new use
disorder
disorders
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282832A
Other languages
English (en)
Inventor
John Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001282832A1 publication Critical patent/AU2001282832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001282832A 2000-09-05 2001-08-31 New use of quetiapine Abandoned AU2001282832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0003126 2000-09-05
SE0003126A SE0003126D0 (sv) 2000-09-05 2000-09-05 Method of treatment
PCT/SE2001/001879 WO2002020019A1 (en) 2000-09-05 2001-08-31 New use of quetiapine

Publications (1)

Publication Number Publication Date
AU2001282832A1 true AU2001282832A1 (en) 2002-03-22

Family

ID=20280890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282832A Abandoned AU2001282832A1 (en) 2000-09-05 2001-08-31 New use of quetiapine

Country Status (10)

Country Link
US (2) US7338948B2 (enExample)
EP (1) EP1326616B1 (enExample)
JP (1) JP2004508333A (enExample)
AT (1) ATE291920T1 (enExample)
AU (1) AU2001282832A1 (enExample)
DE (1) DE60109799T2 (enExample)
ES (1) ES2238469T3 (enExample)
PT (1) PT1326616E (enExample)
SE (1) SE0003126D0 (enExample)
WO (1) WO2002020019A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
PT1326616E (pt) 2005-06-30
DE60109799D1 (de) 2005-05-04
JP2004508333A (ja) 2004-03-18
US20080108597A1 (en) 2008-05-08
EP1326616B1 (en) 2005-03-30
EP1326616A1 (en) 2003-07-16
ES2238469T3 (es) 2005-09-01
US20040034010A1 (en) 2004-02-19
ATE291920T1 (de) 2005-04-15
WO2002020019A1 (en) 2002-03-14
SE0003126D0 (sv) 2000-09-05
DE60109799T2 (de) 2006-02-16
HK1056120A1 (en) 2004-02-06
US7338948B2 (en) 2008-03-04

Similar Documents

Publication Publication Date Title
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
AU3831301A (en) Method for treating ocular pain
GB0111186D0 (en) Novel compounds
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AP2004002995A0 (en) Combination therapy for the treatment of cancer
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
AU2001282832A1 (en) New use of quetiapine
TR200200278T2 (tr) Kalsilitik bileşimler
AU2001244834A1 (en) Novel strain for decomposing tmah, and method of wastewater treatment using the same
WO2002040006A3 (en) Treatment of anxiety disorders
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU3899100A (en) Treatment of hyperactivity disorders
AU2002235202A1 (en) Treatment of bone disorders by modulation of fgfr3
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
AU6121901A (en) Felbamate derived compounds